NCT05165628 - Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

September 24, 2024

Study Completion Date

September 24, 2024

Conditions

Diabetic Foot UlcerCutaneous Ulcer

Interventions

COMBINATION_PRODUCT

CYP-006TK

CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing

Trial Locations (4)

5000

Central Adelaide Local Health Network, Adelaide

Unknown

Fiona Stanley Hospital, Perth

Royal Perth Hospital, Perth

Sir Charles Gairdner Hospital, Perth